Methylprednisolone and other confounders to spinal cord injury clinical trials.
about
The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injuryFundamentals of clinical outcomes assessment for spinal disorders: study designs, methodologies, and analyses.Dose and chemical modification considerations for continuous cyclic AMP analog delivery to the injured CNSAcute molecular perturbation of inducible nitric oxide synthase with an antisense approach enhances neuronal preservation and functional recovery after contusive spinal cord injuryBridging the lesion-engineering a permissive substrate for nerve regenerationUse of the CatWalk Gait Device to Assess Differences in Locomotion between Genders in Rats Inherently and following Spinal Cord Injury
P2860
Methylprednisolone and other confounders to spinal cord injury clinical trials.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Methylprednisolone and other confounders to spinal cord injury clinical trials.
@ast
Methylprednisolone and other confounders to spinal cord injury clinical trials.
@en
type
label
Methylprednisolone and other confounders to spinal cord injury clinical trials.
@ast
Methylprednisolone and other confounders to spinal cord injury clinical trials.
@en
prefLabel
Methylprednisolone and other confounders to spinal cord injury clinical trials.
@ast
Methylprednisolone and other confounders to spinal cord injury clinical trials.
@en
P356
P1476
Methylprednisolone and other confounders to spinal cord injury clinical trials.
@en
P2093
Damien D Pearse
Marca L Sipski
P304
P356
10.1038/NCPNEURO0221
P577
2006-08-01T00:00:00Z